These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38302750)

  • 1. Neurological and immunological adverse events after pneumococcal conjugate vaccine in children using national immunization programme registry data.
    Kim JH; Yoon D; Lee H; Choe YJ; Shin JY
    Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 38302750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
    Tseng HF; Sy LS; Liu IL; Qian L; Marcy SM; Weintraub E; Yih K; Baxter R; Glanz JM; Donahue J; Naleway A; Nordin J; Jacobsen SJ
    Vaccine; 2013 May; 31(22):2578-83. PubMed ID: 23579258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines.
    Baker MA; Jankosky C; Yih WK; Gruber S; Li L; Cocoros NM; Lipowicz H; Coronel-Moreno C; DeLuccia S; Lin ND; McMahill-Walraven CN; Menschik D; Selvan MS; Selvam N; Chen Tilney R; Zichittella L; Lee GM; Kawai AT
    Vaccine; 2020 Feb; 38(9):2166-2171. PubMed ID: 32019703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting.
    Johnstone SL; Moore DP; Klugman KP; Madhi SA; Groome MJ
    Paediatr Int Child Health; 2020 Feb; 40(1):50-57. PubMed ID: 31156062
    [No Abstract]   [Full Text] [Related]  

  • 9. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results.
    Baker MA; Baer B; Kulldorff M; Zichittella L; Reindel R; DeLuccia S; Lipowicz H; Freitas K; Jin R; Yih WK
    PLoS Med; 2019 Jul; 16(7):e1002844. PubMed ID: 31265459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies.
    Bar-Zeev N; Swarthout TD; Everett DB; Alaerts M; Msefula J; Brown C; Bilima S; Mallewa J; King C; von Gottberg A; Verani JR; Whitney CG; Mwansambo C; Gordon SB; Cunliffe NA; French N; Heyderman RS;
    Lancet Glob Health; 2021 Jul; 9(7):e989-e998. PubMed ID: 34143997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine.
    Yoon D; Jeon HL; Kim JH; Lee H; Shin JY
    JAMA Netw Open; 2024 Jan; 7(1):e2352597. PubMed ID: 38252436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine.
    Wise RP; Iskander J; Pratt RD; Campbell S; Ball R; Pless RP; Braun MM
    JAMA; 2004 Oct; 292(14):1702-10. PubMed ID: 15479935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Children who received PCV-10 vaccine from a two-dose vial without preservative are not more likely to develop injection site abscess compared with those who received pentavalent (DPT-HepB-Hib) vaccine: a longitudinal multi-site study.
    Berhane Y; Worku A; Demissie M; Tesfaye N; Asefa N; Aniemaw W; Weldearegawi B; Kebede Y; Shiferaw T; Worku A; Olijira L; Merdekios B; Ashebir Y; Tadesse T; Dessie Y; Meseret S; Ayele G
    PLoS One; 2014; 9(6):e97376. PubMed ID: 24896582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febrile Seizures After 2010-2011 Trivalent Inactivated Influenza Vaccine.
    Kawai AT; Martin D; Kulldorff M; Li L; Cole DV; McMahill-Walraven CN; Selvam N; Selvan MS; Lee GM
    Pediatrics; 2015 Oct; 136(4):e848-55. PubMed ID: 26371192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months.
    Duffy J; Weintraub E; Hambidge SJ; Jackson LA; Kharbanda EO; Klein NP; Lee GM; Marcy SM; Nakasato CC; Naleway A; Omer SB; Vellozzi C; DeStefano F;
    Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27273711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.